ReviewJournal of translational medicine2024
CD8
Review in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- T cell-mediated immune function in gastric cancer: a bibliometric overview of the last 20 years (2006-2025).Frontiers in oncology · 2026Pooled it
- Article
- B Cells and Tumor Immunometabolism: Emerging Insights into Immune Regulation and Therapeutic Resistance.Antibodies (Basel, Switzerland) · 2026Review
- Angiopoietin-like protein 4 deficiency promotes tumor immune infiltration and CD8Molecular therapy. Oncology · 2026Article
- Immunoediting and precision biomarkers in prostate cancer: The emerging role of liquid biopsy, immune contexture and HLA genotype (Review).International journal of oncology · 2026Review
- Immunological and prognostic impact of NRF2 in high grade serous ovarian cancer.Genes and immunity · 2026Article
- PANoptosis and Immune Remodeling in the Tumor Microenvironment.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- RNF149/RBM25/MYC/PD-L1 axis promotes CD8Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Metabolic enzymes and immune receptors as emerging checkpoints in breast cancer: mechanisms, clinical trials, and therapeutic implications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- LATS2 expression differences in lung adenocarcinoma and lung squamous cell carcinoma analyzed using bioinformatics and experimental approaches.Oncology letters · 2026Article
- Neuropeptide Y as a Neuro-Immune Checkpoint in Cancer.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Review
- Peripheral blood IFN-γ-producing T-cell subsets and soluble IL-2 receptor as independent prognostic biomarkers in NSCLC treated with immune checkpoint inhibitor-based therapy.Discover oncology · 2026Article
- A novel combination for in vivo breast cancer treatment: TAK1 inhibition combined with metformin and Lentinula edodes compounds synergistically reinvigorates CD8Journal of translational medicine · 2026Article
- Review
- T cell-inspired therapeutic delivery platforms: From nanomedicines to cell therapy.Materials today. Bio · 2026Review
- PCSK9-mediated degradation of cell-surface LDL receptors impairs human CD8+ T cell effector functions.iScience · 2026Article
- A Unique Protein Adjuvant for Precision Immunotherapy to Prevent Recurrence of Surgically Resected Colorectal Cancer.Cancers · 2026Review
- Topological Data Analysis of Spatial Protein Expression in Multiplexed Spatial Proteomics Studies.bioRxiv : the preprint server for biology · 2026Article
- T Cell Glycoengineering to Modulate Immune-Tumor Crosstalk: A Universal Non-Genetic Strategy for Enhanced Tumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Abscopal-like antitumor effect induced by localized low-temperature plasma application of normal tissue in mice.Journal of radiation research · 2026Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The immune system in humans is a defense department against both exogenous and endogenous hazards, where CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.